Global Access for Monoclonal Antibodies - Landscape Report (360G-Wellcome-215847_Z_19_Z)
Monoclonal antibodies (mAbs) are safe, effective treatments for many chronic diseases and have had a transformational impact on human health and medicine. However, access to mAb products is limited mostly to developed countries and/or private retail markets. In parallel, the potential for mAbs has expanded to passive immunization and therapy for infectious diseases. Many antibody-based candidates are being tested in clinical studies, but they have an unclear path to broad, affordable global access. The Wellcome Trust has commissioned the International AIDS Vaccine Initiative (lA VI) to prepare a landscape report on the challenges and investment opportunities for affordable global access to mAbs for prevention and therapy in low- and middle-income countries, with an analysis of opportunities to broaden access in high-income countries as a secondary goal. This report will include case studies for marketed antibodies and an application of these learnings to antibodies in development for multiple diseases, including infectious diseases.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Amount Awarded | 243591 |
| Applicant Surname | Sitlani |
| Approval Committee | Internal Decision Panel |
| Award Date | 2019-09-30T00:00:00+00:00 |
| Financial Year | 2018/19 |
| Grant Programme: Title | Discretionary Award – Innovations |
| Internal ID | 215847/Z/19/Z |
| Lead Applicant | Dr Ayesha Sitlani |
| Partnership Value | 243591 |
| Planned Dates: End Date | 2021-05-03T00:00:00+00:00 |
| Planned Dates: Start Date | 2019-04-01T00:00:00+00:00 |
| Recipient Org: Country | United States |
| Region | International |